Significant variation between Cancer Alliances was also observed when considering follow up of dMMR tumours (either germline testing for MSH2/MSH6/PMS2 deficient tumours, or further somatic testing for MLH1 deficient tumours). This evidence concerns the gene MSH2 and neoplasm.